Provided herein are impurities of cinacalcet, (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-(5,6,7,8-tetrahydronaphthalene)methaneamine (tetrahydro cinacalcet impurity), (R)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethaneamine-N-oxide (cinacalcet N-oxide impurity) and (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]methyl]-1-naphthalenemethaneamine (benzylamine impurity); and processes for preparation and isolation thereof. Provided further herein is a highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities.
本文提供了
西那卡塞的杂质,包括(R)-α-甲基-N-[3-[3-(三
氟甲基)苯基]丙基]-1-(5,6,7,8-四氢
萘)
甲胺(四氢
西那卡塞杂质)、(R)-α-甲基-N-[3-[3-(三
氟甲基)苯基]丙基]-1-
萘甲胺-N-氧化物(
西那卡塞N-氧化物杂质)和(R)-α-甲基-N-[3-[3-(三
氟甲基)苯基]甲基]-1-
萘甲胺(
苄胺杂质);以及制备和分离它们的过程。本文还提供了高纯度的
西那卡塞或其药学上可接受的盐,其基本上不含杂质,以及制备该药物的过程和包含高纯度的
西那卡塞或其药学上可接受的盐,其基本上不含杂质的制药组合物。